Boundless Bio (BOLD)

• Market cap: $31.7M
• 1 day: 8.40%
• 5 days: 18.33%
• 1 month: -15.48%
• 3 months: -43.87%
• 6 months: -53.14%
• Year to date: -47.99%
• 1 year: -87.42%
• 5 years: -90.04%
• 10 years: -90.61%
• Sector: Healthcare
• Industry: Biotechnology

About: Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Employees: 64

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

600% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 4

13% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 8

2% more funds holding

Funds holding: 54 [Q3] → 55 (+1) [Q4]

0.81% less ownership

Funds ownership: 58.93% [Q3] → 58.13% (-0.81%) [Q4]

17% less capital invested

Capital invested by funds: $45.5M [Q3] → $37.6M (-$7.93M) [Q4]